BioCentury
ARTICLE | Company News

Pharmexa, Kael Co. Ltd. deal

May 4, 2009 7:00 AM UTC

Kael's VaxOnco Inc. subsidiary will acquire Pharmexa's Pharmexa- Epimmune Inc. subsidiary for € 440,000 ($579,436). VaxOnco gains IP covering infectious disease epitopes for HPV, HCV, HBV, HIV, malar...